Skip to main content

REVIEW article

Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1465881
This article is part of the Research Topic Regulatory Pathways Orchestrate T Cell Activity in Tumor Immunology and Organ Transplantation View all articles

Glucagon-like peptide-1 receptor agonists in neoplastic diseases

Provisionally accepted
Lisan Ji Lisan Ji 1Xianzhen He Xianzhen He 2Xinwen Min Xinwen Min 1Handong Yang Handong Yang 1Wenwen Wu Wenwen Wu 3Hao Xu Hao Xu 1Jun Chen Jun Chen 1*Aihua Mei Aihua Mei 1
  • 1 Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan, China
  • 2 Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China
  • 3 School of Public Health and Management, Hubei University of Medicine, Shiyan, Hubei, China

The final, formatted version of the article will be published soon.

    Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.

    Keywords: GLP-1RA, tumor diseases, function, Mechanism, agonists

    Received: 18 Jul 2024; Accepted: 28 Aug 2024.

    Copyright: © 2024 Ji, He, Min, Yang, Wu, Xu, Chen and Mei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jun Chen, Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.